OTCMKTS:CPHRF

Cipher Pharmaceuticals Competitors

$1.09
+0.03 (+2.83 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.09
Now: $1.09
$1.09
50-Day Range
$0.69
MA: $0.89
$1.17
52-Week Range
$0.53
Now: $1.09
$1.17
Volume505 shs
Average Volume16,166 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Cipher Pharmaceuticals (OTCMKTS:CPHRF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying CPHRF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Cipher Pharmaceuticals, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Abacus Health Products (OTCMKTS:ABAHF) and Cipher Pharmaceuticals (OTCMKTS:CPHRF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Abacus Health Products and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abacus Health ProductsN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Abacus Health Products and Cipher Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abacus Health ProductsN/AN/AN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Abacus Health Products and Cipher Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abacus Health Products0000N/A
Cipher Pharmaceuticals01202.67

Cipher Pharmaceuticals has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Cipher Pharmaceuticals' higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Abacus Health Products.

Institutional and Insider Ownership

25.1% of Cipher Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cipher Pharmaceuticals beats Abacus Health Products on 3 of the 3 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and Cipher Pharmaceuticals (OTCMKTS:CPHRF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Acreage and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcreageN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Acreage and Cipher Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcreageN/AN/AN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Acreage and Cipher Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acreage01202.67
Cipher Pharmaceuticals01202.67

Acreage currently has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Cipher Pharmaceuticals has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Acreage's higher probable upside, equities analysts plainly believe Acreage is more favorable than Cipher Pharmaceuticals.

Institutional and Insider Ownership

25.1% of Cipher Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Applied Biosciences (OTCMKTS:APPB) and Cipher Pharmaceuticals (OTCMKTS:CPHRF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Applied Biosciences and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied BiosciencesN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Applied Biosciences and Cipher Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied BiosciencesN/AN/AN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Applied Biosciences and Cipher Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Biosciences0000N/A
Cipher Pharmaceuticals01202.67

Cipher Pharmaceuticals has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Cipher Pharmaceuticals' higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Applied Biosciences.

Institutional and Insider Ownership

25.1% of Cipher Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cipher Pharmaceuticals beats Applied Biosciences on 3 of the 3 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Cipher Pharmaceuticals (OTCMKTS:CPHRF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Analyst Ratings

This is a summary of recent recommendations for Ayr Strategies and Cipher Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Cipher Pharmaceuticals01202.67

Ayr Strategies currently has a consensus price target of $34.8571, indicating a potential upside of 63.96%. Cipher Pharmaceuticals has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Cipher Pharmaceuticals' higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Ayr Strategies.

Institutional and Insider Ownership

25.1% of Cipher Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Ayr Strategies and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Ayr Strategies and Cipher Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/AN/AN/A

Cipher Pharmaceuticals (OTCMKTS:CPHRF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cipher Pharmaceuticals and Can B, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals01202.67
Can B0000N/A

Cipher Pharmaceuticals currently has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Cipher Pharmaceuticals' higher probable upside, research analysts clearly believe Cipher Pharmaceuticals is more favorable than Can B.

Institutional & Insider Ownership

25.1% of Cipher Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cipher Pharmaceuticals and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
Can BN/AN/AN/A

Valuation and Earnings

This table compares Cipher Pharmaceuticals and Can B's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Summary

Cipher Pharmaceuticals beats Can B on 3 of the 3 factors compared between the two stocks.

Cipher Pharmaceuticals (OTCMKTS:CPHRF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Valuation and Earnings

This table compares Cipher Pharmaceuticals and Cansortium's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsN/AN/AN/AN/AN/A
CansortiumN/AN/AN/AN/AN/A

Profitability

This table compares Cipher Pharmaceuticals and Cansortium's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
CansortiumN/AN/AN/A

Institutional & Insider Ownership

25.1% of Cipher Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cipher Pharmaceuticals and Cansortium, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals01202.67
Cansortium00103.00

Cipher Pharmaceuticals currently has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Cansortium has a consensus price target of $1.20, indicating a potential upside of 18.81%. Given Cipher Pharmaceuticals' higher probable upside, research analysts clearly believe Cipher Pharmaceuticals is more favorable than Cansortium.

Summary

Cipher Pharmaceuticals beats Cansortium on 3 of the 4 factors compared between the two stocks.


Cipher Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84+5.4%$0.00N/A0.00Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77+0.0%$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.22+77.3%$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AYRSF
Ayr Strategies
1.4$21.26+0.0%$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.49+6.1%$0.00N/A0.00Gap Up
Cansortium logo
CNTMF
Cansortium
0.9$1.01+3.0%$0.00N/A0.00Gap Down
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.06+1.0%$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.10+10.3%$0.00N/A0.00Gap Up
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.22+4.5%$0.00N/A0.00News Coverage
Gap Up
Cosmos logo
COSM
Cosmos
0.5$5.40+1.9%$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.5$12.17+2.7%$0.00N/A0.00Gap Up
Curaleaf logo
CURLF
Curaleaf
1.6$13.84+1.2%$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00+0.0%$0.00N/A0.00Decrease in Short Interest
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.14+0.0%$0.00N/A0.00Gap Down
EVIO logo
EVIO
EVIO
0.6$0.00+0.0%$0.00N/A0.00News Coverage
Gap Down
Flower One logo
FLOOF
Flower One
0.4$0.22+9.1%$0.00N/A0.00Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05+0.0%$0.00N/A0.00News Coverage
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01+0.0%$0.00N/A0.00Gap Up
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$29.31+0.6%$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.62+3.2%$0.00N/A0.00Increase in Short Interest
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.82+0.7%$0.00N/A0.00
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01+0.0%$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.68+0.0%$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.22+0.0%$0.00N/A0.00Gap Down
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.32+0.0%$0.00N/A0.00Decrease in Short Interest
News Coverage
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04+0.0%$0.00N/A0.00Decrease in Short Interest
Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.07+0.0%$0.00N/A0.00Gap Up
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.40+2.5%$0.00N/A0.00Decrease in Short Interest
KHTRF
Knight Therapeutics
1.2$4.22+0.2%$0.00N/A0.00High Trading Volume
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01+0.0%$0.00N/A0.00Increase in Short Interest
News Coverage
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.04+0.0%$0.00N/A0.00Gap Up
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.38+0.0%$0.00N/A0.00Analyst Report
Increase in Short Interest
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.30+6.6%$0.00N/A0.00Increase in Short Interest
Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.76+1.1%$0.00N/A0.00Increase in Short Interest
MJardin Group logo
MJARF
MJardin Group
1.1$0.07+0.0%$0.00N/A0.00Gap Down
MYHI
Mountain High Acquisitions
0.5$0.02+0.0%$0.00N/A0.00Gap Up
PHCEF
Pharmacielo
0.7$1.25+7.2%$0.00N/A0.00
Plus Products logo
PLPRF
Plus Products
1.1$0.52+7.7%$0.00N/A0.00Decrease in Short Interest
Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00+0.0%$0.00N/A0.00
PCYN
Procyon
0.4$0.60+0.0%$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01+0.0%$0.00N/A0.00Decrease in Short Interest
News Coverage
SANP
Santo Mining
0.5$0.01+0.0%$0.00N/A0.00News Coverage
Gap Down
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.39+1.2%$0.00N/A0.00Increase in Short Interest
Gap Down
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40+0.0%$0.00N/A0.00News Coverage
TerrAscend logo
TRSSF
TerrAscend
1.7$10.02+0.0%$0.00N/A0.00Analyst Report
Increase in Short Interest
Gap Down
The Flowr logo
FLWPF
The Flowr
1.5$0.25+0.0%$0.00N/A0.00
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.0$0.30+3.3%$0.00N/A0.00Analyst Report
News Coverage
Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.